• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球血液微小RNA分析揭示了埃博拉疫苗rVSVΔG-ZEBOV-GP免疫原性的早期特征。

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.

作者信息

Vianello Eleonora, Persson Josefine, Andersson Björn, van Veen Suzanne, Dias Thomaz Lüscher, Santoro Francesco, Östensson Malin, Obudulu Ogonna, Agbajogu Christopher, Torkzadeh Sara, Nakaya Helder I, Medaglini Donata, Siegrist Claire-Anne, Ottenhoff Tom H M, Harandi Ali M

机构信息

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

出版信息

iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15.

DOI:10.1016/j.isci.2023.108574
PMID:38162033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10755791/
Abstract

The vectored Ebola vaccine rVSVΔG-ZEBOV-GP elicits protection against Ebola Virus Disease (EVD). In a study of forty-eight healthy adult volunteers who received either the rVSVΔG-ZEBOV-GP vaccine or placebo, we profiled intracellular microRNAs (miRNAs) from whole blood cells (WB) and circulating miRNAs from serum-derived extracellular vesicles (EV) at baseline and longitudinally following vaccination. Further, we identified early miRNA signatures associated with ZEBOV-specific IgG antibody responses at baseline and up to one year post-vaccination, and pinpointed target mRNA transcripts and pathways correlated to miRNAs whose expression was altered after vaccination by using systems biology approaches. Several miRNAs were differentially expressed (DE) and miRNA signatures predicted high or low IgG ZEBOV-specific antibody levels with high classification performance. The top miRNA discriminators were WB-miR-6810, EV-miR-7151-3p, and EV-miR-4426. An eight-miRNA antibody predictive signature was associated with immune-related target mRNAs and pathways. These findings provide valuable insights into early blood biomarkers associated with rVSVΔG-ZEBOV-GP vaccine-induced IgG antibody responses.

摘要

载体埃博拉疫苗rVSVΔG-ZEBOV-GP可诱导机体对埃博拉病毒病(EVD)产生保护作用。在一项针对48名健康成年志愿者的研究中,这些志愿者分别接种了rVSVΔG-ZEBOV-GP疫苗或安慰剂,我们在基线期以及接种疫苗后的纵向时间点,对全血细胞(WB)中的细胞内微小RNA(miRNA)和血清来源的细胞外囊泡(EV)中的循环miRNA进行了分析。此外,我们确定了在基线期以及接种疫苗后长达一年的时间里,与ZEBOV特异性IgG抗体反应相关的早期miRNA特征,并通过系统生物学方法,找出了与接种疫苗后表达发生改变的miRNA相关的靶mRNA转录本和信号通路。有几种miRNA存在差异表达(DE),并且miRNA特征能够以较高的分类性能预测高或低的IgG ZEBOV特异性抗体水平。最具鉴别力的miRNA是WB-miR-6810、EV-miR-7151-3p和EV-miR-4426。一个由8种miRNA组成的抗体预测特征与免疫相关的靶mRNA和信号通路相关。这些发现为与rVSVΔG-ZEBOV-GP疫苗诱导的IgG抗体反应相关的早期血液生物标志物提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/d4a736fe9cfe/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/4afe50a63448/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/fe11749929d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/499706b68ba5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/47600c811fba/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/85561bfb3a66/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/2596f39f2109/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/0cbc6f3bf54e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/d38a1841f47f/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/d4a736fe9cfe/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/4afe50a63448/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/fe11749929d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/499706b68ba5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/47600c811fba/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/85561bfb3a66/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/2596f39f2109/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/0cbc6f3bf54e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/d38a1841f47f/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/10755791/d4a736fe9cfe/gr8.jpg

相似文献

1
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.全球血液微小RNA分析揭示了埃博拉疫苗rVSVΔG-ZEBOV-GP免疫原性的早期特征。
iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15.
2
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.在欧洲、非洲和北美洲的成年人群中,埃博拉病毒疫苗 rVSVΔG-ZEBOV-GP 诱导的转录组特征:分子生物标志物研究。
Lancet Microbe. 2022 Feb;3(2):e113-e123. doi: 10.1016/S2666-5247(21)00235-4. Epub 2021 Dec 6.
3
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.rVSVΔG-ZEBOV-GP 埃博拉疫苗(ERVEBO®)接种 1 或 2 剂后的免疫原性和疫苗脱落:在儿童和成人中进行的一项 2 期、随机、安慰剂对照试验的结果。
Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693.
4
Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.在撒哈拉以南非洲儿科人群中,载体埃博拉疫苗 rVSV-ΔG-ZEBOV-GP 的复制、安全性和免疫原性:在加蓬兰巴雷内居住的 1-12 岁儿童中进行的一项随机对照、开放性标签试验。
J Infect. 2024 Oct;89(4):106237. doi: 10.1016/j.jinf.2024.106237. Epub 2024 Aug 8.
5
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.rVSVΔG-ZEBOV-GP 疫苗的免疫原性、批次一致性和安全性延长:健康成年人中进行的 3 期随机、双盲、安慰剂对照研究。
J Infect Dis. 2019 Aug 30;220(7):1127-1135. doi: 10.1093/infdis/jiz241.
6
PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.利比里亚公共卫生应对措施中 rVSVΔG-ZEBOV-GP 作为部分内容的 PREVAIL I 群疫苗接种研究。
J Infect Dis. 2019 Apr 19;219(10):1634-1641. doi: 10.1093/infdis/jiy698.
7
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.重组水疱性口炎病毒载体扎伊尔埃博拉病毒疫苗(rVSVΔG-ZEBOV-GP)保护相关性的评估:2/3期临床试验数据的事后分析
Lancet Microbe. 2021 Feb;2(2):e70-e78. doi: 10.1016/S2666-5247(20)30198-1. Epub 2021 Feb 2.
8
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.体液和细胞免疫应答由 rVSVΔG-ZEBOV-GP 疫苗引起的在 2013-2016 年期间在几内亚的西非埃博拉疫情一线工作人员。
Vaccine. 2020 Jun 26;38(31):4877-4884. doi: 10.1016/j.vaccine.2020.04.066. Epub 2020 Jun 1.
9
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.重组水疱性口炎病毒ΔG-ZEBOV-GP埃博拉疫苗在加蓬兰巴雷内成人和儿童中的安全性和免疫原性:一项I期随机试验
PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct.
10
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.rVSVΔG-ZEBOV-GP 埃博拉疫苗(ERVEBO®)在非洲临床试验参与者中的免疫原性按年龄、性别和基线 GP-ELISA 滴度划分:三项 2/3 期试验的事后分析。
Vaccine. 2022 Nov 2;40(46):6599-6606. doi: 10.1016/j.vaccine.2022.09.037. Epub 2022 Oct 5.

引用本文的文献

1
Profile of Selected MicroRNAs as Markers of Sex-Specific Anti-S/RBD Response to COVID-19 mRNA Vaccine in Health Care Workers.医护人员中选定的微小RNA作为COVID-19 mRNA疫苗性别特异性抗刺突蛋白受体结合域(S/RBD)反应标志物的概况
Int J Mol Sci. 2025 Aug 7;26(15):7636. doi: 10.3390/ijms26157636.
2
Plasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines.血浆微小RNA用于从抗成瘾疫苗中筛选产生抗体的最佳患者。
Vaccines (Basel). 2025 Feb 13;13(2):181. doi: 10.3390/vaccines13020181.
3
Altered expression of miRNA profile in peripheral blood mononuclear cells following the third dose of inactivated COVID-19 vaccine.

本文引用的文献

1
Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination.泛疫苗分析揭示了预测疫苗接种后抗体反应的固有免疫内型。
Nat Immunol. 2022 Dec;23(12):1777-1787. doi: 10.1038/s41590-022-01329-5. Epub 2022 Oct 31.
2
miR-25-3p ameliorates SAE by targeting the TLR4/NLRP3 axis.miR-25-3p 通过靶向 TLR4/NLRP3 轴改善 SAE。
Metab Brain Dis. 2022 Aug;37(6):1803-1813. doi: 10.1007/s11011-022-01017-1. Epub 2022 Jun 15.
3
miR-382-5p promotes cell invasion in hepatocellular carcinoma by targeting PTEN to activate PI3K/Akt signaling pathway.
新型冠状病毒灭活疫苗第三剂接种后外周血单个核细胞中miRNA谱的表达变化
PeerJ. 2025 Jan 22;13:e18856. doi: 10.7717/peerj.18856. eCollection 2025.
4
Identification and Potential Roles of Human MicroRNAs in Ebola Virus Infection and Disease Pathogenesis.人类微小RNA在埃博拉病毒感染及疾病发病机制中的鉴定及潜在作用
Genes (Basel). 2024 Mar 25;15(4):403. doi: 10.3390/genes15040403.
miR-382-5p 通过靶向 PTEN 激活 PI3K/Akt 信号通路促进肝癌细胞侵袭。
World J Surg Oncol. 2022 Jun 2;20(1):175. doi: 10.1186/s12957-022-02638-7.
4
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.在欧洲、非洲和北美洲的成年人群中,埃博拉病毒疫苗 rVSVΔG-ZEBOV-GP 诱导的转录组特征:分子生物标志物研究。
Lancet Microbe. 2022 Feb;3(2):e113-e123. doi: 10.1016/S2666-5247(21)00235-4. Epub 2021 Dec 6.
5
Therapeutically harnessing extracellular vesicles.治疗性利用细胞外囊泡。
Nat Rev Drug Discov. 2022 May;21(5):379-399. doi: 10.1038/s41573-022-00410-w. Epub 2022 Mar 2.
6
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination.与新冠病毒疫苗接种后不良反应、促炎细胞因子及抗体产生相关的循环细胞外囊泡微小核糖核酸
NPJ Vaccines. 2022 Feb 8;7(1):16. doi: 10.1038/s41541-022-00439-3.
7
The reactome pathway knowledgebase 2022.反应体通路知识库2022版。
Nucleic Acids Res. 2022 Jan 7;50(D1):D687-D692. doi: 10.1093/nar/gkab1028.
8
miR-486-5p Serves as a Diagnostic Biomarker for Sepsis and Its Predictive Value for Clinical Outcomes.miR-486-5p作为脓毒症的诊断生物标志物及其对临床结局的预测价值。
J Inflamm Res. 2021 Jul 30;14:3687-3695. doi: 10.2147/JIR.S323433. eCollection 2021.
9
Downregulation of miR-98-5p expression induces interleukin-6 expression in rheumatoid fibroblast-like synoviocytes.miR-98-5p 表达下调诱导类风湿成纤维样滑膜细胞中白细胞介素-6 的表达。
Int J Rheum Dis. 2021 Aug;24(8):1024-1031. doi: 10.1111/1756-185X.14160. Epub 2021 Jun 21.
10
Genetic Determinants Highlight the Existence of Shared Etiopathogenetic Mechanisms Characterizing Age-Related Macular Degeneration and Neurodegenerative Disorders.遗传决定因素凸显了年龄相关性黄斑变性和神经退行性疾病共有的病因发病机制的存在。
Front Neurol. 2021 May 31;12:626066. doi: 10.3389/fneur.2021.626066. eCollection 2021.